Common questions

Wegovy FAQ: Uses, Results, Side Effects, Cost, and Coverage

Wegovy (semaglutide) is a GLP-1 medicine for weight loss, heart risk, and liver disease, taken as a weekly injection or daily pill. Trials show 13.6% to 14.9% average weight loss; a health-record cohort of semaglutide and tirzepatide users averaged 8.7% at one year.

Last checked September 14, 2026·25 sources cited·Wegovy

Clay-style still life of an injection pen, a tablet blister pack, a bathroom scale, and three question-mark shapes above them.

Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.

Wegovy is the brand name for semaglutide, a GLP-1 receptor agonist medicine that comes as a once-weekly injection and a once-daily pill ^[2]. It is FDA-approved for weight loss in adults and children aged 12 and older with obesity, for reducing the risk of major cardiovascular events in adults with established heart disease, and for treating noncirrhotic MASH (a form of fatty liver disease) in adults ^[2]. In the main 68-week trial, adults without diabetes lost an average of 14.9% of their body weight on the 2.4 mg injection versus 2.4% on placebo ^[4]. Outside of trials, a health-record cohort of adults taking injectable semaglutide or tirzepatide averaged 8.7% weight loss at one year, largely because people stop the drug or stay on lower doses ^[10].

This FAQ covers the questions people ask before and after starting Wegovy: what it treats, how dosing works, what results to expect, side effects, what happens after stopping, and what it costs with and without insurance.

What is Wegovy and what is it approved for?

Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist containing semaglutide, sold as an injection and as tablets ^[2]. The injection is approved, along with a reduced-calorie diet and increased physical activity, for three uses: reducing the risk of major adverse cardiovascular events (cardiovascular death, nonfatal heart attack, or nonfatal stroke) in adults with established cardiovascular disease and either obesity or overweight; weight reduction in adults and children aged 12 and older with obesity, and in adults with overweight plus at least one weight-related condition; and treatment of noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3) in adults ^[2]. The tablets are approved for cardiovascular risk reduction and weight reduction in adults only [2, 3].

The cardiovascular approval rests on the SELECT trial, which enrolled 17,604 adults aged 45 and older with cardiovascular disease and a BMI of 27 or higher, without diabetes ^[6]. Over a mean follow-up of 39.8 months, a primary cardiovascular event occurred in 6.5% of the semaglutide group versus 8.0% of the placebo group, a hazard ratio of 0.80 ^[6].

The MASH indication was granted on August 15, 2025 under accelerated approval, making Wegovy the first GLP-1 receptor agonist approved for MASH ^[14]. In the ESSENCE trial at week 72, 63% of people on Wegovy achieved resolution of steatohepatitis without worsening fibrosis versus 34% on placebo, and 37% achieved improvement in fibrosis without worsening steatohepatitis versus 22% on placebo ^[14]. A confirmatory part of that trial is ongoing ^[14].

What forms and doses does Wegovy come in?

The injection comes in single-dose pens of 0.25, 0.5, 1, 1.7, and 2.4 mg, plus a higher-dose 7.2 mg pen sold as Wegovy HD ^[2]. The label says to start at 0.25 mg once weekly for 4 weeks and step up every 4 weeks, with 2.4 mg once weekly as the usual maintenance dose ^[2]. For adults who tolerate 2.4 mg for at least 4 weeks and for whom additional weight reduction is clinically indicated, the label allows increasing to a maximum of 7.2 mg once weekly ^[2]. Wegovy HD was approved by the FDA 54 days after filing, under the agency’s National Priority Voucher pilot program ^[12].

The tablets come in 1.5, 4, 9, and 25 mg strengths ^[2]. The label starts patients at 1.5 mg once daily for 30 days, steps up every 30 days, and lists 25 mg once daily as the maintenance dose for adults ^[2]. The pill was approved on December 22, 2025 as the first oral GLP-1 for weight loss, and Novo Nordisk planned to launch it in the US in early January 2026 ^[13].

The pill has a strict dosing routine: take it once daily on an empty stomach in the morning with water only, up to 4 ounces; swallow it whole; and wait at least 30 minutes before eating food, drinking beverages, or taking other oral medicines ^[2].

How much weight can you lose on Wegovy?

In trials, average weight loss ranged from about 13% to 15% of body weight over roughly 64 to 72 weeks, depending on the population and the form of the drug.

Trial	Population	Dose and duration	Result
STEP 1 ^[4]	1,961 adults without diabetes	2.4 mg injection, 68 weeks	-14.9% vs -2.4% placebo; 50.5% lost 15%+
OASIS 4 [8, 13]	307 adults without diabetes	25 mg pill, 64 weeks	-13.6% vs -2.2% placebo
STEP UP T2D ^[7]	512 adults with obesity and type 2 diabetes	7.2 mg injection, 72 weeks	-13.2% vs -3.9% placebo
STEP TEENS ^[9]	Adolescents ages 12 to under 18	2.4 mg injection, 68 weeks	BMI -16.1% vs +0.6% placebo

In OASIS 4, a hypothetical analysis estimating the effect if everyone took the pill as assigned put weight loss at -16.6% ^[13]. The STEP UP T2D figures apply only to people with obesity and type 2 diabetes; that trial also found 7.2 mg lowered HbA1c more than placebo ^[7].

Why do real-world results run lower than trial results?

A retrospective study of electronic health records from a large health system in Ohio and Florida followed 7,881 adults without type 2 diabetes who started injectable semaglutide (6,109 people) or tirzepatide (1,772 people) between 2021 and 2023 ^[10]. Mean weight loss at one year across the combined cohort was 8.7% ^[10].

The gap from trial numbers traced largely to staying on the drug: people who stopped within 3 months lost 3.6% on average, people who stopped later lost 6.8%, and people who continued lost 11.9% ^[10]. In addition, 80.8% of the cohort was on low maintenance doses, which the authors also credited for the gap ^[10]. Because the cohort mixed semaglutide and tirzepatide, the 8.7% figure is not a Wegovy-only number.

What are the most common Wegovy side effects?

The most common adverse reactions, reported in 5% or more of adults or pediatric patients aged 12 and older, are nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia (altered skin sensation), headache, fatigue, dyspepsia, dizziness, abdominal distension, burping, gas, reflux, and hair loss ^[2]. In STEP 1, nausea and diarrhea were the most common events, typically transient and mild to moderate; 4.5% of the semaglutide group stopped treatment for gastrointestinal events versus 0.8% on placebo ^[4].

Dysesthesia deserves attention at higher doses. Across trials in people with and without type 2 diabetes, dysesthesia occurred in 22% of people on the 7.2 mg injection versus 6% on 2.4 mg and 0.3% on placebo, and the incidence rises with dosage and blood levels of the drug ^[2]. In STEP UP T2D, dysesthesia was reported by 18.9% of people on 7.2 mg versus 4.9% on 2.4 mg ^[7]. The FDA has said these skin sensation reactions generally resolved on their own or with dose reduction, and that it is investigating further ^[12]. Discontinuation for adverse reactions was 5% on 7.2 mg, 5% on 2.4 mg, and 2% on placebo ^[2].

Other label data: reactions related to low blood pressure occurred in 1.3% of Wegovy-treated adults versus 0.4% on placebo, and fainting in 0.8% versus 0.2%, with some cases linked to fluid loss from gastrointestinal reactions; the label advises monitoring heart rate ^[2].

What serious warnings come with Wegovy?

Wegovy carries a boxed warning about thyroid C-cell tumors seen in rodents at clinically relevant exposures; whether the drug causes such tumors, including medullary thyroid carcinoma, in humans is unknown ^[2]. The drug is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 ^[2].

Other warnings on the label include acute pancreatitis, acute gallbladder disease, hypoglycemia when combined with insulin or sulfonylureas, acute kidney injury from volume depletion, severe gastrointestinal reactions, serious allergic reactions, diabetic retinopathy complications in people with type 2 diabetes, and pulmonary aspiration during general anesthesia or deep sedation ^[2]. Wegovy should not be used together with other semaglutide-containing products or any other GLP-1 receptor agonist ^[2].

The manufacturer’s safety information advises stopping Wegovy 2 months before a planned pregnancy, and breastfeeding is not recommended while taking the tablets ^[15].

What happens when you stop taking Wegovy?

Weight tends to come back. In the STEP 1 off-treatment extension, 327 participants who had lost an average of 17.3% of body weight by week 68 regained 11.6 percentage points by week 120, leaving a net loss of 5.6%—about two-thirds of the prior loss regained ^[5]. Most cardiometabolic improvements also reverted toward baseline, and the authors concluded that ongoing treatment is needed to maintain weight and health improvements ^[5].

How much does Wegovy cost without insurance?

NovoCare lists the following self-pay prices, which Novo Nordisk can change at any time ^[15]:

Product	Dose	Self-pay price per month
Pill	1.5 mg	$149
Pill	4 mg	$199
Pill	9 mg and 25 mg	$299
Pen	0.25 mg and 0.5 mg (new patients, first 2 fills)	$199 through December 31, 2026
Pen	0.25 to 2.4 mg	$349
Wegovy HD pen	7.2 mg	$399

A month is defined as one bottle of 30 tablets or one box of 4 pens ^[15]. With commercial insurance, a NovoCare savings offer lists payment as little as $25 per month, subject to a maximum savings of $100 per month; government beneficiaries are excluded from that offer ^[15]. People with government insurance can use the self-pay prices, but that spending does not count toward a deductible or out-of-pocket limit ^[16].

On February 24, 2026, Novo Nordisk announced that the list price of Wegovy will drop to $675 per month effective January 1, 2027, a cut of about 50%, and that self-pay prices are unaffected ^[17].

Does Medicare cover Wegovy?

Yes, through a temporary program. The Medicare GLP-1 Bridge, run by CMS, runs from July 1, 2026 to December 31, 2027 and charges eligible Part D beneficiaries a $50 monthly copay ^[18]. It operates outside the Part D benefit, so the Part D deductible does not apply, the copay does not count toward out-of-pocket costs, and there is no low-income subsidy ^[18].

The program covers all doses of Wegovy, both pen and pill, with no enrollment required; beneficiaries must have Part D, and access runs through prior authorization handled by the prescriber and pharmacist ^[19]. Medical criteria include being 18 or older with a BMI of 35 or higher, or a BMI of 30 or higher with heart failure (preserved ejection fraction) or chronic kidney disease stage 3a or above ^[19].

How does Wegovy compare with Zepbound?

In SURMOUNT-5, 751 adults with obesity and no type 2 diabetes were assigned openly to the maximum tolerated dose of tirzepatide (Zepbound, 10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg) for 72 weeks ^[11]. At week 72, the tirzepatide group lost an average of 20.2% of body weight versus 13.7% for semaglutide ^[11]. The most common adverse events in both groups were gastrointestinal, mostly mild to moderate and occurring mainly during dose escalation ^[11].

Sources

Frequently asked questions

Is Wegovy the same drug as Ozempic?

Both medicines contain semaglutide, the same GLP-1 receptor agonist, but they are separate products. Novo Nordisk lists Ozempic among its medicines for type 2 diabetes and Wegovy among its medicines for obesity. The Wegovy label states that Wegovy should not be used with other semaglutide-containing products or any other GLP-1 receptor agonist.

Can teenagers use Wegovy or the Wegovy pill?

The Wegovy injection is approved for weight reduction in people aged 12 and older with obesity. In STEP TEENS, BMI fell 16.1% over 68 weeks with semaglutide versus a 0.6% increase on placebo. The Wegovy pill is not approved for people under 18.

Can you take the Wegovy pill with coffee or breakfast?

No. The label says to take the tablet once daily on an empty stomach in the morning with water only, up to 4 ounces, swallowed whole, and to wait at least 30 minutes before eating food, drinking beverages, or taking other oral medicines. Coffee and breakfast both fall under that 30-minute wait.

Does Wegovy cause hair loss?

Hair loss is listed among the most common adverse reactions, those reported in 5% or more of adults or pediatric patients aged 12 and older, on the Wegovy label. It appears in the label's common-reaction list alongside nausea, diarrhea, fatigue, dizziness, and other reactions. Anyone concerned about hair loss while taking Wegovy can raise it with their prescriber.

Does Wegovy cause muscle loss?

In a STEP 1 body-composition substudy of 140 participants, total fat mass fell 19.3% with semaglutide, while total lean body mass decreased 9.7% but its proportion relative to total body mass increased. The authors reported a greater lean-to-fat mass ratio with larger weight loss.

Who qualifies for Wegovy HD?

Per the label, the 7.2 mg dose is an option only for adults who have tolerated 2.4 mg for at least 4 weeks and for whom additional weight reduction is clinically indicated. Dysesthesia was reported by 22% of people on 7.2 mg versus 6% on 2.4 mg and 0.3% on placebo, so the decision belongs with a prescriber.

Does Medicare pay for Wegovy?

Through the Medicare GLP-1 Bridge, eligible Part D beneficiaries pay a $50 monthly copay for all Wegovy doses, pen and pill, from July 1, 2026 to December 31, 2027 [18, 19]. The copay does not count toward the Part D deductible or out-of-pocket costs, and there is no low-income subsidy.

This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.